Salestools LogoSalestools
Agents IA Salestools
Solutions
Ressources
Entreprise
Tarifs
Salestools Logo

Salestools

L'agent IA #1 pour les équipes de vente et Go-to-Market. Vendez plus, plus vite, avec moins d'effort.

Produit

  • Agents de vente IA
  • Données d'intention
  • Données technologiques
  • Suivi des visiteurs
  • Copilote
  • Vente sociale

Solutions

  • Service client
  • E-commerce
  • SaaS
  • Entreprise
  • Petite entreprise

Ressources

  • Le rapport
  • Documentation
  • Référence API
  • Centre d'aide
  • Blog
  • Études de cas
  • Webinaires

Entreprise

  • À propos
  • Carrières
  • Presse
  • Contact
  • Partenaires

Nos bureaux

  • New York, HQ
  • Bucarest, Laboratoire de recherche IA
  • Zug, Suisse

© 2026 Salestools. Tous droits réservés.

Conditions relatives aux données et sécuritéPolitique de confidentialitéConditions de serviceAcceptable Use
Tous les systèmes opérationnels
Salestools LogoSalestools
Agents IA Salestools
Solutions
Ressources
Entreprise
Tarifs
Back to Reports
Biotech

AbCellera

AbCellera raises $555M Series B at $5.7B valuation

2389 Health Sciences Mall, Vancouver, BC V6T 1Z3, CanadaJune 12, 20241 min read
Total Raised
$555M
Valuation
$5.7B
Latest Round
Series B
Employees
400+

AbCellera: Series B Funding Round

AbCellera has successfully raised $555M in Series B funding, reaching a valuation of $5.7B.

Company Overview

Antibody discovery platform

Funding Details

The Series B round was led by Peter Thiel, with participation from Eli Lilly, Fast Forward Innovations, DCVC Bio.

Company Information

  • Headquarters: 2389 Health Sciences Mall, Vancouver, BC V6T 1Z3, Canada
  • Founded: 2012
  • Employees: 400+
  • Category: Biotech

Investment

AbCellera plans to use the funds to accelerate product development, expand its team, and scale operations globally.

About the Investors

  • Peter Thiel: Verified investor in Series B
  • Eli Lilly: Verified investor in Series B
  • Fast Forward Innovations: Verified investor in Series B
  • DCVC Bio: Verified investor in Series B

Company Info

Headquarters
2389 Health Sciences Mall, Vancouver, BC V6T 1Z3, Canada
Founded
2012
Team Size
400+
Last Round
$555M(Jun 2024)

Investors (4)

P
Peter ThielLead
Lead Investor
Verified investor in Series B
E
Eli Lilly
Investor
Verified investor in Series B
F
Fast Forward Innovations
Investor
Verified investor in Series B
D
DCVC Bio
Investor
Verified investor in Series B

Topics

verified(3079)real-funding(3079)series-b(280)abcellerabiotech2389-health-sciences-mall

Share

Related Reports

Biotech
AusperBio

AusperBio Raises $73M Series B

Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials

David Chen
David Chen
Dec 30, 2025
0 min read•$73M Series B
Biotech
Orna Therapeutics

Orna Therapeutics Raises $251M Series B

Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases

Emma Rodriguez
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics

Forge Biologics Raises $120M Series C

Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C

Turn your sales ideas into reality today

Start your 14-day Pro trial today. No credit card required.

Start building for free